Treatment of painful bone metastases

Nature Reviews Clinical Oncology

Volumn 7, Issue 4, 2010, Pages 220-229

  Rades, Dirk ^a   Schild, Steven E ^b   Abrahm, Janet L ^c  

^a UNIVERSITY OF LÜBECK   (Germany)

^b MAYO CLINIC   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CODEINE; CORTICOSTEROID; DENOSUMAB; FENTANYL; HYDROMORPHONE; KETOROLAC TROMETAMOL; LACTULOSE; LEVORPHANOL; LEXIDRONAM SAMARIUM SM 153; METHADONE; MORPHINE; NABUMETONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; OXYMORPHONE; PAMIDRONIC ACID; PARACETAMOL; PETHIDINE; PLACEBO; PROCHLORPERAZINE; SENNA EXTRACT; STRONTIUM 89; STRONTIUM CHLORIDE; TRAMADOL; UNINDEXED DRUG; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; BONE DISEASE; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPRESSION FRACTURE; CONSTIPATION; CONTINUOUS INFUSION; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL TOXICITY; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; KYPHOPLASTY; NAUSEA; NONHUMAN; PAIN; PATHOLOGIC FRACTURE; PATHOPHYSIOLOGY; PERCUTANEOUS VERTEBROPLASTY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RETREATMENT; REVIEW; SKIN MANIFESTATION; SPINAL CORD COMPRESSION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

BONE NEOPLASMS; CONFIDENCE INTERVALS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; KYPHOPLASTY; OSTEOLYSIS; PAIN; PROGNOSIS; RADIOTHERAPY; RISK;

EID: 77950520827     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.17     Document Type: Review

References (82)

1. Coleman, R. E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12 (Suppl.), S6243-S6249 (2006).
2. Mundy, G. R. Mechanisms of bone metastasis. Cancer 80, 1546-1556 (1997).
3. Mercadente, S. Malignant bone pain: pathophysiology and treatment. Pain 69, 1-18 (1997). (Pubitemid 27081402)
4. Coleman, R. E. & Rubens, R. The clinical course of bone metastases in breast cancer. Br. J. Cancer 77, 336-340 (1987).
5. Fang, K. & Peng, C. Predicting the probability of bone metastasis through histological grading of prostate carcinoma: a retrospective correlative analysis of 81 autopsy cases with ante-mortem transurethral resection specimens. J. Urol. 57, 715-720 (1983). (Pubitemid 13009783)
6. Parfitt, A. M. Bone remodeling, normal and abnormal: a biological basis for the understanding of cancer-related bone disease and its treatment. Can. J. Oncol. 5 (Suppl. 1), 1-10 (1995).
7. Raisz, L. G. Physiology and pathophysiology of bone remodeling. Clin. Chem. 45, 1353-1358 (1999).
8. Choong, P. F. The molecular basis of skeletal metastases. Clin. Orthop. Relat. Res. 415 (Suppl.), S19-S30 (2003).
9. Abrahm, J. L. A Physician's Guide to Pain and Symptom Management in Cancer Patients, 2nd edn (Johns Hopkins University Press, Baltimore, 2005).
10. Miaskowski, C. et al. Guideline for the Management of Cancer Pain in Adults and Children, APS Clinical Practice Guidelines Series, No.3. Glenview, Ill.; American Pain Society (2005).
11. [No authors listed] Tramadol: A new oral analgesic. Med. Lett. 37, 59-62 (1995).
12. Martinez-Zapata, M. J., Roque, M., Alonso-Coello, P. & Catala, E. Calcitonin for metastatic bone pain. Cochrane Database of Systematic Reviews 3, CD003223 (2006).
13. Joishy, S. K. & Walsh, D. The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome. J. Pain Symptom Manage. 16, 334-339 (1998). (Pubitemid 28545915)
14. Brown, C. R. et al. Comparison of repeat doses of intramuscular ketorolac tromethamine and morphine sulfate for analgesia after major surgery. Pharmacotherapy 10, S45-S50 (1990).
15. Feldman, H. I. et al. Parenteral ketorolac: The risk for acute renal failure. Ann. Intern. Med. 126, 193-199 (1997). (Pubitemid 27061572)
16. McQuay, H. J. & Moore, A. in Oxford Textbook of Palliative Medicine (eds Doyle, D., Hanks, G., Cherny, N. & Calman, K.) 348 (Oxford University Press, Oxford, 2005).
17. Abrahm, J. L. Advances in pain management for older adult patients. Clin. Geriatr. Med. 16, 269-311 (2000).
18. Chan, F. K. et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N. Engl. J. Med. 347, 2104-2110 (2002).
19. Yeomans, N. D. et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal inflammatory drugs. N. Engl. J. Med. 338, 719-726 (1998). (Pubitemid 28115090)
20. Congregation for Doctrine of the Faith: Declaration on euthanasia. Washington, DC, United States Catholic Conference, 6 (1980).
21. John Paul II. Catechism of the Catholic Church, Euthanasia (Eds Imprimi Potest + Joseph Cardinal Ratzinger, Interdicasterial Commission for the Catechism of the Catholic Church. 549 (St Paul Books and Media, Libreria Editrice vaticana, Rome, 1994).
22. O'Rourke, K. Pain relief: the perspective of Catholic tradition. J. Pain Symptom Manage. 7, 485-491 (1992). (Pubitemid 23009077)
23. Nicholson, B. Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain Pract. 9, 71-81 (2009).
24. Schaiova, L. et al. Consensus guideline on parenteral methadone use in pain and palliative care. Palliative and Supportive Care 6, 165-176 (2008).
25. Warfield, C. A. Guidelines for routine use of controlled-release oral morphine sulfate tablets. Semin. Oncol. 2 (Suppl. 1), 36-47 (1993).
26. Hagen, N. A. & Babul, N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 79, 1428-1437 (1997). (Pubitemid 27143251)
27. Finley, R. S. Bisphosphonates in the treatment of bone metastases. Semin. Oncol. 129 (Suppl. 4), 132-138 (2002).
28. Purohit, O. P., Anthony, C., Radstone, C. R., Owen, J. & Coleman, R. E. High-dose intravenous pamidronate for metastatic bone pain. Br. J. Cancer 70, 554-558 (1994). (Pubitemid 24268564)
29. Berenson, J. R. et al. American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. 20, 3719-3736 (2002).
30. Pistevou-Gombaki, K., Eleftheriadis, N., Sofroniadis, I., Makris, P. & Kouloulias, v. Palliative treatment of painful bone metastases from non-Hodgkin lympoma with disodium pamidronate. J. Exp. Clin. Cancer Res. 21, 429-432 (2002).
31. Santini, D., Fratto, M. E., vincenzi, B., Galluzzo, S. & Tonini, G. Zoledronic acid in the management of metastatic bone disease. Expert Opin. Biol. Ther. 6, 1333-1348 (2006). (Pubitemid 44875687)
32. Saad, F. et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94, 1458-1468 (2002).
33. Rosen, L. S. et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase II, double-blind, randomized trial-The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. 21, 3150-3157 (2003).
34. Rosen, L. S. et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100, 36-43 (2004). (Pubitemid 37553537)
35. Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J. & Engroff, S. L. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J. Oral Maxillofac. Surg. 62, 527-534 (2004). (Pubitemid 38542516)
36. Body, J. J. et al. Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J. Bone Miner. Res. doi:10.1359/jbmr.090810.
37. Yaccoby, S. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109, 2106-2111 (2007). (Pubitemid 46348212)
38. Buchbinder, R. et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N. Engl. J. Med. 361, 557-568 (2009).
39. Lewiecki, E. M. Augmentation procedures for osteoporotic vertebral fractures-an ongoing experiment or emerging standard of care? South. Med. J. 99, 449-450 (2006).
40. Bouza, C., Lopez-Cuadrado, T., Cediel, P., Saz-Parkinson, Z. & Amate, J. M. Balloon kyphoplasty in malignant spinal fractures: a systematic review and meta-analysis. BMC Palliative Care 8, 12-19 (2009).
41. Masala, S. et al. Future directions in percutaneous vertebroplasty. Radiol. Med. 114, 976-983 (2009).
42. Silberstein, E. B. The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin. Oncol. 3 (Suppl. 2), 10-21 (1993). (Pubitemid 23170167)
43. Robinson, R. G., Preston, D. F., Baxter, K. G., Dusing, R. W. & Spicer, J. A. Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin. Oncol. 20 (Suppl. 2), 44-48 (1993). (Pubitemid 23170173)
44. Serafini, A. N. et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled trial. J. Clin. Oncol. 16, 1574-1581 (1998).
45. Amouzegar-Hashemi, F., Behrouzi, H., Kazemian, A., Zarpak, B. & Haddad, P. Single versus multiple fractions of palliative radiotherapy for bone metastases: a randomized clinical trial in Iranian patients. Curr. Oncol. 15, 36-39 (2008).
46. Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiother. Oncol. 52, 111-121 (1999).
47. Foro Arnalot, P. et al. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother. Oncol. 89, 150-155 (2008).
48. Gaze, M. N. et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. Radiother. Oncol. 45, 109-116 (1997).
49. Hartsell, W. F. et al. Randomized trial of shortversus long-course radiotherapy for palliation of painful bone metastases. J. Natl Cancer Inst. 97, 798-804 (2005).
50. Hoskin, P. J. et al. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother. Oncol. 23, 74-78 (1992).
51. Jeremic, B. et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int. J. Radiat. Oncol. Biol. Phys. 42, 161-167 (1998). (Pubitemid 28435609)
52. Koswig, S. & Budach, v. Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs 1 time 8 Gy). A prospective study. Strahlenther. Onkol. 175, 500-508 (1999).
53. Nielsen, O. S., Bentzen, S. M., Sandberg, E., Gadeberg, C. C. & Timothy, A. R. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother. Oncol. 47, 233-240 (1998). (Pubitemid 28293643)
54. Niewald, M. et al. Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases. Int. J. Radiat. Oncol. Biol. Phys. 36, 1085-1089 (1996). (Pubitemid 27014494)
55. Okawa, T., Kita, M., Goto, M., Nishijima, H. & Miyaji, N. Randomized prospective clinical study of small, large and twice-a-day fraction radiotherapy for painful bone metastases. Radiother. Oncol. 13, 99-104 (1988).
56. Rasmusson, B. et al. Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year follow-up. Radiother. Oncol. 34, 179-184 (1995).
57. Roos, D. E. et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother. Oncol. 75, 54-63 (2005). (Pubitemid 40616795)
58. Steenland, E. et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother. Oncol. 52, 101-109 (1999). (Pubitemid 29461077)
59. Tong, D., Gillick, L. & Hendrickson, F. R. The palliation of symptomatic osseous metastases. Final results of the study by the Radiation Therapy Oncology Group. Cancer 50, 893-899 (1982).
60. Chow, E. et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother. Oncol. 64, 275-280 (2002). (Pubitemid 35254020)
61. Wu, J. S. et al. Meta-analysis of dosefractionation radiotherapy trials for the palliation of painful bone metastases. Int. J. Radiat. Oncol. Biol. Phys. 55, 594-605 (2003). (Pubitemid 36170000)
62. Sze, W. M., Shelley, M. D., Held, I., Wilt, T. J. & Mason, M. D. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy--a systematic review of randomised trials. Clin. Oncol. (R. Coll. Radiol.) 15, 345-352 (2003).
63. Chow, E., Harris, K., Fan, G., Tsao, M. N. & Sze, W. M. Palliative radiotherapy trials for bone metastases: a systematic review. J. Clin. Oncol. 25, 1423-1436 (2007). (Pubitemid 46706892)
64. Jeremic, B., Shibamoto, Y. & Igrutinovic, I. Single 4 Gy re-irradiation for painful bone metastases following single fraction radiotherapy. Radiother. Oncol. 52, 123-127 (1999). (Pubitemid 29461079)
65. Mithal, N., Needham, P. & Hoskin, P. Retreatment with radiotherapy for painful bone metastases. Int. J. Radiat. Oncol. Biol. Phys. 29, 1011-1014 (1994). (Pubitemid 24278968)
66. Ryu, S. et al. Image-guided and intensitymodulated radiosurgery for patients with spinal metastasis. Cancer 97, 2013-2018 (2003). (Pubitemid 36397280)
67. Milker-Zabel, S. et al. Clinical results of retreatment of vertebral bone metastases by stereotactic conformal radiotherapy and intensity-modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 55, 162-167 (2003). (Pubitemid 36024166)
68. Gerszten, P. C., Burton, S. A., Ozhasoglu, C. & Welch, W. C. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine 32, 193-199 (2007). (Pubitemid 46105806)
69. van der Linden, Y. et al. Patients with favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch Bone Metastasis Study. Radiother. Oncol. 78, 245-253 (2006).
70. Joiner, M. C. & van der Kogel, A. J. in The Linear-Quadratic Approach to Fractionation and Calculation of Isoeffect Relationships (ed. Steel, G. G.) 106 (Oxford University Press, New York, 1997).
71. vassiliou, v. et al. Combining systemic bisphosphonates with palliative external beam radiotherapy or bone-targeted radionuclide therapy: interactions and effectiveness. Clin. Oncol. 21, 665-667 (2009).
72. Liang, J. G. et al. Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis [Chinese]. Zhonghua Zhong Liu Za Zhi 27, 180-182 (2005).
73. Chow, E., Ling, A., Davis, L., Panzarella, T. & Danjoux, C. Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiother. Oncol. 75, 64-69 (2005). (Pubitemid 40616796)
74. Chow, E. et al. Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases-a pilot study. Support. Care Cancer 15, 643-647 (2007). (Pubitemid 47034993)
75. Loblaw, D. A. et al. Pain flare in patients with bone metastases after palliative radiotherapy - a nested randomized control trial. Support. Care Cancer 15, 451-455 (2007). (Pubitemid 46697018)
76. Katagiri, H. et al. Prognostic factors and a scoring system for patients with skeletal metastasis. J. Bone Joint Surg. Br. 87, 698-703 (2005). (Pubitemid 40711646)
77. van der Linden, Y. M. et al. Prediction of survival in patients with metastases in the spinal column. Results based on a randomized trial of radiotherapy. Cancer 103, 320-328 (2005).
78. Rades, D. et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J. Clin. Oncol. 23, 3366-3375 (2005). (Pubitemid 46243481)
79. Rades, D. et al. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J. Clin. Oncol. 24, 3388-3393 (2006). (Pubitemid 46638894)
80. Rades, D. et al. Preliminary results of the SCORE (Spinal Cord Compression Recurrence Evaluation) study comparing short-course versus long-course radiotherapy for local control of malignant epidural spinal cord compression. Int. J. Radiat. Oncol. Biol. Phys. 73, 228-234 (2009).
81. Rades, D., Dunst, J. & Schild, S. E. The first score predicting overall survival in patients with metastatic spinal cord compression. Cancer 112, 157-161 (2007).
82. Rades, D. et al. validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. Cancer (in press).